FDA delays bone marrow drug
6th Sep 2005, 01:02 GMT
MGI Pharma and SuperGen have received an approvable letter from the FDA for Dacogen injection for the treatment of MDS, a group of diseases that affects the bone marrow and can progress to acute leukemia.
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol